Research

Adherence

GLP-1 monotherapy (liraglutide, semaglutide) is associated with high discontinuation rates due to gastrointestinal side effects, limiting long-term adherence.

Be aware that GLP-1 monotherapy can cause significant gastrointestinal side effects, leading to high discontinuation rates. Discuss titration strategies with your provider to minimize these effects.

GoodQualifiesHIGH confidence
GLP-1R mimetics are often discontinued within 24-months, owing to gastrointestinal side-effects, meaning long-term application of these agents in obesity is questioned.
Ryan A. Lafferty et al. · Expert Opinion on Pharmacotherapy · 2023

Why this rating

Based on clinical trial data and real-world usage statistics cited in the paper.

Source

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

Ryan A. Lafferty et al. · Expert Opinion on Pharmacotherapy · 2023

DOI 10.1080/14656566.2023.2192865

narrative_reviewCited 42×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →